Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Platelet rich plasma helps speed healing and bone formation following tooth removal

The use of platelet rich plasma (PRP) following tooth removal appears to speed healing and bone formation, according to an article in the Journal of Oral Implantology.

20 Apr 2010

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL) in Vienna, Austria. Efficacy and safety data from the ASTUTE study are expected in the summer of 2010.

17 Apr 2010

3M files lawsuit against Andover Healthcare over CoFlex 2 Layer Compression System

3M and 3M Innovative Properties Co. filed a lawsuit in the U.S. District Court for the District of Minnesota today against Andover Healthcare Inc. seeking injunctive relief and damages regarding Andover's CoFlex 2 Layer Compression System.

16 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today jointly announced that the companies have entered into a license, development and commercialization agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications.

1 Apr 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

READ 3 study for DME begins enrolling participants

A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

27 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Dyax to use proceeds of public offering for commercialization and distribution activities of KALBITOR

Dyax Corp. today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price to the public of $3.25 per share. The gross proceeds from the sale of shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.8 million. The offering is expected to close on or about March 30, 2010, subject to customary closing conditions.

26 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

Xifaxan drug receives FDA approval

The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.

25 Mar 2010

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

AMAG Pharmaceuticals, Inc. today announced that one abstract has been accepted for presentation at the National Kidney Foundation 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL.

19 Mar 2010

Modulating body's inflammatory response may help fight serious infection

Treating virulent influenza, sepsis, and other potentially deadly infections long has focused on looking for ways to kill viruses and bacteria. But new research from the University of Utah and Utah State University shows that modulating the body's own overeager inflammatory response to infection may help save more lives.

18 Mar 2010

Kinetic Concepts’ Prevena Incision Management System may help reduce post-operative complications

Kinetic Concepts, Inc. today announced the initial European and Canadian launch of the Prevena™ Incision Management System, the first and only powered negative pressure product designed specifically for management of surgically closed incisions.

18 Mar 2010

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Edema News and Research

Further Reading

Platelet rich plasma helps speed healing and bone formation following tooth removal

CryoSTAT cold therapy for hemorrhoids

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients

3M files lawsuit against Andover Healthcare over CoFlex 2 Layer Compression System

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Parents lack understanding of causes, signs and symptoms of dehydration in children

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

READ 3 study for DME begins enrolling participants

New topical drug may help treat diabetic eye disease

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Dyax to use proceeds of public offering for commercialization and distribution activities of KALBITOR

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Xifaxan drug receives FDA approval

AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010

Modulating body's inflammatory response may help fight serious infection

Kinetic Concepts’ Prevena Incision Management System may help reduce post-operative complications

ONGLYZA-metformin combination: FDA accepts NDA for review

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News